Experimental drug cocktail aims to shrink esophageal tumors before surgery
NCT ID NCT06654297
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether combining two drugs—camrelizumab (an immunotherapy) and palbociclib (a targeted therapy)—is safe and feasible when given before surgery for esophageal cancer. Six adults with resectable esophageal squamous cell carcinoma will receive the drugs for about three months, then undergo surgery. The main goals are to check for side effects and ensure the treatment doesn't delay surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab and palbociclib
- What this could lead to
- If this combination proves safe and feasible, it could lead to a new pre-surgery treatment option for esophageal cancer that may improve tumor shrinkage before surgery.
- What could go wrong
- This is a very early phase 1 trial with only 6 participants, so results may not apply to larger groups. The drugs can cause side effects like immune reactions or low blood cell counts, and the combination may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads